Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by
Infinium Global Research on the epinephrine autoinjector market provides in-depth
analysis of segments and sub-segments in the global as well as regional
epinephrine autoinjector market. The study also highlights the impact of
drivers, restraints, and macro indicators on the global and regional
epinephrine autoinjector market over the short term as well as long term. The
report is a comprehensive presentation of trends, forecast and dollar values of the global epinephrine autoinjector market. According to the report, the global
epinephrine autoinjector market is projected to grow at a CAGR of nearly 8%
over the forecast period of 2022-2028.
The global epinephrine autoinjector market was valued at over USD 2 Billion in 2022 and is expected to
reach nearly USD 3.5 Billion in 2028, with a CAGR of nearly 8% during the
forecast period. Epinephrine autoinjectors are known as hand-held medical devices
utilized by patients who have severe allergies. Epinephrine injections are
particularly utilized to treat the life-threatening allergic reactions caused
by insect bites, medications, or stings. Epinephrine injections are available
as prefilled automatic injection devices with the hormone in liquid form. An
increasing number of patient-support efforts and innovative product development
by major market players will provide lucrative growth opportunities for the
market. The growing demand for epinephrine auto-injectors for rapid emergency
response is projected to propel market growth. The key element driving the
epinephrine auto-injector market growth in the high dosage sector is the rising
incidence of anaphylaxis in adults, particularly among the old population.
The key factors supporting the
growth of the epinephrine autoinjectors involve the demand for autoinjectors
instead of conventional syringes, increasing prevalence of allergies, and
increased focus of the major market players on the development of
chlorofluorocarbon free epinephrine injectors during the forecast period. The
rising incidence and awareness of allergies in the population are also
increasing the demand for the autoinjector. Technological advancements in
Research and Development activities such as chlorofluorocarbon-free epinephrine
auto-injector inhalers with the use of hydrofluoroalkane propellants will drive the expansion of the market. Furthermore, high demand for auto-injectors rather
than conventional devices such as typical epinephrine auto-injector inhalers
are subsidizing the growth of the Market during the forecast period. However, the
high cost of autoinjectors and regulatory hurdles can hinder epinephrine
growth during the forecast period. Moreover, Patient assistance programs are carried
out for uninsured people, continuous product modification, and demand for
automatic injection devices to further create growth opportunities for the
epinephrine autoinjector market.
The COVID-19 pandemic had mixed
effects on the worldwide epinephrine autoinjector market during the covid-19
pandemic. Most non-essential procedures and in-hospital therapies were deferred
within half of 2020 to forestall the spread of the infection and ease the
toll on healthcare infrastructure. consistent with researchers at Indiana
University, healthcare visits decreased by around 40% within the first six
weeks of the pandemic in the US, from early March to mid-April. However, the
pandemic’s overall effect on the autoinjectors is known as positive, especially
within the forecast period, because of several factors. Firstly, the demand for
effective home care and remote monitoring has increased the relevance of
autoinjectors for patients to conveniently and simply manage chronic illnesses
and allergies without visiting the hospital.
The global epinephrine
autoinjector market is segmented into the Asia Pacific, North America, Europe,
the Middle East & Africa, and South America. On the basis of region, North
America has the largest market share in the epinephrine autoinjector market on
account of improved healthcare infrastructure, and the adoption of high-cost
autoinjectors rather in contrast to conventional injecting methods. Asia Pacific
is expected to grow at the highest CAGR over the forecast period Because of the
increasing number of people afflicted with various allergies and increasing
awareness about epinephrine autoinjectors among the population. Moreover,
increasing investment in the development of new advanced autoinjectors by major
market players is projected to enhance the growth during the forecast period.
The report on the global epinephrine
autoinjector market covers segments such as dosage, and end-user. On the basis
of dosage, the sub-markets include 0.15 mg epinephrine autoinjector, 0.3 mg
epinephrine autoinjector, and 0.5 mg epinephrine autoinjector. On the basis of
end-user, the sub-markets include hospital, clinics, and individual.
The report provides profiles of
the companies in the market such as Pfizer Inc., Mylan Inc., ALK Abello, Sanofi
SA, Lincoln Medical Ltd, Teva Pharmaceuticals Ltd, Antares Pharma Inc., Lincoln
Medical Ltd., Impax Laboratories, Inc., and Bausch & Lomb Incorporated.
The report provides deep insights
into demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of the epinephrine autoinjector market. Moreover, the study highlights
current market trends and provides forecast from 2022-2028. We also have
highlighted future trends in the market that will affect the demand during the
forecast period. Moreover, the competitive analysis given in each regional
market brings insight into the market share of the leading players.
Please Choose One of them.